Tag: Eosinophilic esophagitis

Allakos (NASDAQ: ALLK) today released data from ENIGMA 2, a 24-week randomized, double-blind, placebo-controlled phase 3 study of lirentelimab in patients with biopsy-confirmed eosinophilic gastritis (EG) and / or ...

Le cours de l'action Allakos Inc (NASDAQ : ALLK) – une société de biotechnologie développant le lirentelimab (AK002) pour le traitement des maladies liées aux éosinophiles et aux mastocytes – a chuté de plus de 85 % avant...

Allakos (ALLK) announces data from ENIGMA 2, a 24-week phase 3 study of lirentelimab in patients with biopsy-confirmed eosinophilic gastritis and / or eosinophilic duodenitis and KRYPTOS, ...